Evidence map›Paper›PMID 25212686›Full record

ArticleRetrovirology2014

Early immune adaptation in HIV-1 revealed by population-level approaches.

Eric Martin, Jonathan M Carlson, Anh Q Le, Denis R Chopera, Rachel McGovern, Manal A Rahman, Carmond Ng, Heiko Jessen, Anthony D Kelleher, Martin Markowitz and 5 more

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Immune Control of HIV.Journal of life sciences (Westlake Village, Calif.) · 2019
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 4 countries.

Eric Martin
Jonathan M Carlson
Anh Q Le
Denis R Chopera
Rachel McGovern
Manal A Rahman
Carmond Ng
Heiko Jessen
Anthony D Kelleher
Martin Markowitz
Todd M Allen
M-J Milloy
Mary Carrington
Mark A Wainberg
Zabrina L Brumme
AIDS Vancouver · CASimon Fraser University · CALeidos (United States) · USMcGill University · CAMicrosoft (United States) · USRagon Institute of MGH, MIT and Harvard · USRockefeller University · USUniversity of British Columbia · CAUniversity of KwaZulu-Natal · ZAUNSW Sydney · AU

Funding

Effects of genetic polymorphism in MHC, KIR, and related loci on human diseaseZIABC010791 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CARRINGTON, MARY N. · 2009 to 2025
$18.2M
SYRINGE ACCESS AND RISK FACTORS ON HIV TRANSMISSIONR01DA011591 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI KERR, THOMAS · 1998 to 2014
$5.9M
Impacts of universal access to HIV/AIDS care among HIV+ injection drug usersR01DA021525 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI MILLOY, M-J · 2007 to 2016
$5.8M
CCR NIH HHS HHSN261200800001CCIHR HOP-115700CIHR MOP-93536Intramural NIH HHSNCI NIH HHS HHSN261200800001ENIDA NIH HHS R01 DA011591NIDA NIH HHS R01DA011591NIDA NIH HHS R01 DA021525NIDA NIH HHS R01DA021525
6 · The paper itself

Abstract

backgroundThe reproducible nature of HIV-1 escape from HLA-restricted CD8+ T-cell responses allows the identification of HLA-associated viral polymorphisms "at the population level" - that is, via analysis of cross-sectional, linked HLA/HIV-1 genotypes by statistical association. However, elucidating their timing of selection traditionally requires detailed longitudinal studies, which are challenging to undertake on a large scale. We investigate whether the extent and relative timecourse of immune-driven HIV adaptation can be inferred via comparative cross-sectional analysis of independent early and chronic infection cohorts.

resultsSimilarly-powered datasets of linked HLA/HIV-1 genotypes from individuals with early (median < 3 months) and chronic untreated HIV-1 subtype B infection, matched for size (N > 200/dataset), HLA class I and HIV-1 Gag/Pol/Nef diversity, were established. These datasets were first used to define a list of 162 known HLA-associated polymorphisms detectable at the population level in cohorts of the present size and host/viral genetic composition. Of these 162 known HLA-associated polymorphisms, 15% (occurring at 14 Gag, Pol and Nef codons) were already detectable via statistical association in the early infection dataset at p ≤ 0.01 (q < 0.2) - identifying them as the most consistently rapidly escaping sites in HIV-1. Among these were known rapidly-escaping sites (e.g. B*57-Gag-T242N) and others not previously appreciated to be reproducibly rapidly selected (e.g. A*31:01-associated adaptations at Gag codons 397, 401 and 403). Escape prevalence in early infection correlated strongly with first-year escape rates (Pearson's R = 0.68, p = 0.0001), supporting cross-sectional parameters as reliable indicators of longitudinally-derived measures. Comparative analysis of early and chronic datasets revealed that, on average, the prevalence of HLA-associated polymorphisms more than doubles between these two infection stages in persons harboring the relevant HLA (p < 0.0001, consistent with frequent and reproducible escape), but remains relatively stable in persons lacking the HLA (p = 0.15, consistent with slow reversion). Published HLA-specific Hazard Ratios for progression to AIDS correlated positively with average escape prevalence in early infection (Pearson's R = 0.53, p = 0.028), consistent with high early within-host HIV-1 adaptation (via rapid escape and/or frequent polymorphism transmission) as a correlate of progression.

conclusionCross-sectional host/viral genotype datasets represent an underutilized resource to identify reproducible early pathways of HIV-1 adaptation and identify correlates of protective immunity.

Indexed as

Adaptation, PhysiologicalImmune EvasionCross-Sectional Studiesgag Gene Products, Human Immunodeficiency VirusHistocompatibility Antigens Class IHIV-1HIV InfectionsHumansnef Gene Products, Human Immunodeficiency Virusgag Gene Products, Human Immunodeficiency VirusHistocompatibility Antigens Class Inef Gene Products, Human Immunodeficiency Virus

Identifiers

PMID25212686
PMCPMC4190299
OpenAlexW2100540576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.